tiprankstipranks
Trending News
More News >
Cytokinetics (CYTK)
NASDAQ:CYTK
US Market
Advertisement

Cytokinetics (CYTK) Stock Forecast & Price Target

Compare
1,154 Followers
See the Price Targets and Ratings of:

CYTK Analyst Ratings

Strong Buy
18Ratings
Strong Buy
15 Buy
3 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$79.86
▲(41.80% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $79.86 with a high forecast of $120.00 and a low forecast of $41.00. The average price target represents a 41.80% change from the last price of $56.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","121":"$121","52.75":"$52.8","75.5":"$75.5","98.25":"$98.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$79.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,52.75,75.5,98.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.84,60.77538461538462,65.71076923076923,70.64615384615385,75.58153846153846,80.51692307692308,85.4523076923077,90.3876923076923,95.32307692307693,100.25846153846155,105.19384615384615,110.12923076923077,115.0646153846154,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.84,57.68769230769231,59.535384615384615,61.38307692307693,63.23076923076923,65.07846153846154,66.92615384615385,68.77384615384615,70.62153846153846,72.46923076923076,74.31692307692308,76.16461538461539,78.01230769230769,{"y":79.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.84,54.698461538461544,53.55692307692308,52.41538461538462,51.27384615384616,50.13230769230769,48.99076923076923,47.84923076923077,46.70769230769231,45.566153846153846,44.424615384615386,43.28307692307692,42.14153846153846,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$79.86Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CYTK
Bank of America Securities
Bank of America Securities
$52$56
Hold
-0.57%
Downside
Reiterated
10/02/25
Bank of America Securities Sticks to Their Hold Rating for Cytokinetics (CYTK)
J.P. Morgan Analyst forecast on CYTK
J.P. Morgan
J.P. Morgan
Buy
Reiterated
09/30/25
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics' Stock Outlook
Barclays Analyst forecast on CYTK
Barclays
Barclays
$71
Buy
26.07%
Upside
Reiterated
09/30/25
Barclays Remains a Buy on Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CYTK
Morgan Stanley
Morgan Stanley
$65
Buy
15.41%
Upside
Reiterated
09/29/25
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for CytokineticsWe note that mavacamten in ODYSSEY-HCM, which failed to meet its dual primary endpoints (KCCQ-23 CSS and pVO2) at wk 48, showed least-squares mean change in the KCCQ-CSS of 13.1 points for mavacamten vs. 10.4 points for placebo (higher than expected vs. ~6 point placebo in Ph2 MAVERICK) for between-group difference of 2.7 points (P = 0.06) (see our note HERE). Aficamten also improved cardiac biomarkers, with both NT-proBNP and high-sensitivity cardiac troponin I rapidly declining by Week 12 and remaining low through Week 96 ( Exhibit 3 ). There was a modest reduction in left ventricular ejection fraction (LVEF) from hyperdynamic at baseline to within normal range at Week 12 (-6.2%; p<0.0001). Over the treatment period, four patients had LVEF <50% which were reversible after down titration or a short treatment interruption.
Stifel Nicolaus Analyst forecast on CYTK
Stifel Nicolaus
Stifel Nicolaus
$96
Buy
70.45%
Upside
Reiterated
09/29/25
Stifel Nicolaus Remains a Buy on Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
H.C. Wainwright
H.C. Wainwright
$120
Buy
113.07%
Upside
Reiterated
09/29/25
Cytokinetics' Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock OutlookValuation and potential impediments to achieving price target. We reiterate our Buy rating and $120 price target. Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate for capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.
B. Riley Securities Analyst forecast on CYTK
B. Riley Securities
B. Riley Securities
$74$80
Buy
42.05%
Upside
Reiterated
09/22/25
Cytokinetics price target raised to $80 from $74 at B. RileyCytokinetics price target raised to $80 from $74 at B. Riley
RBC Capital Analyst forecast on CYTK
RBC Capital
RBC Capital
$80$82
Buy
45.60%
Upside
Reiterated
09/08/25
RBC Capital Remains a Buy on Cytokinetics (CYTK)
Evercore ISI Analyst forecast on CYTK
Evercore ISI
Evercore ISI
$60$80
Buy
42.05%
Upside
Reiterated
09/03/25
Evercore ISI Sticks to Their Buy Rating for Cytokinetics (CYTK)
Citi
$77$84
Buy
49.15%
Upside
Reiterated
09/03/25
Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results
Jefferies Analyst forecast on CYTK
Jefferies
Jefferies
$80
Buy
42.05%
Upside
Reiterated
09/03/25
Cytokinetics (CYTK) Gets a Buy from Jefferies
Needham
$72
Buy
27.84%
Upside
Reiterated
09/02/25
Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials
Truist Financial Analyst forecast on CYTK
Truist Financial
Truist Financial
Buy
Reiterated
09/02/25
Cytokinetics (CYTK) Gets a Buy from Truist Financial
Leerink Partners Analyst forecast on CYTK
Leerink Partners
Leerink Partners
Buy
Reiterated
09/02/25
Buy Rating Justified for Cytokinetics Due to Aficamten's Advantages in HCM Treatment
UBS
$47$41
Hold
-27.20%
Downside
Reiterated
09/01/25
Cytokinetics (CYTK) Receives a Hold from UBS
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CYTK
Bank of America Securities
Bank of America Securities
$52$56
Hold
-0.57%
Downside
Reiterated
10/02/25
Bank of America Securities Sticks to Their Hold Rating for Cytokinetics (CYTK)
J.P. Morgan Analyst forecast on CYTK
J.P. Morgan
J.P. Morgan
Buy
Reiterated
09/30/25
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics' Stock Outlook
Barclays Analyst forecast on CYTK
Barclays
Barclays
$71
Buy
26.07%
Upside
Reiterated
09/30/25
Barclays Remains a Buy on Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CYTK
Morgan Stanley
Morgan Stanley
$65
Buy
15.41%
Upside
Reiterated
09/29/25
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for CytokineticsWe note that mavacamten in ODYSSEY-HCM, which failed to meet its dual primary endpoints (KCCQ-23 CSS and pVO2) at wk 48, showed least-squares mean change in the KCCQ-CSS of 13.1 points for mavacamten vs. 10.4 points for placebo (higher than expected vs. ~6 point placebo in Ph2 MAVERICK) for between-group difference of 2.7 points (P = 0.06) (see our note HERE). Aficamten also improved cardiac biomarkers, with both NT-proBNP and high-sensitivity cardiac troponin I rapidly declining by Week 12 and remaining low through Week 96 ( Exhibit 3 ). There was a modest reduction in left ventricular ejection fraction (LVEF) from hyperdynamic at baseline to within normal range at Week 12 (-6.2%; p<0.0001). Over the treatment period, four patients had LVEF <50% which were reversible after down titration or a short treatment interruption.
Stifel Nicolaus Analyst forecast on CYTK
Stifel Nicolaus
Stifel Nicolaus
$96
Buy
70.45%
Upside
Reiterated
09/29/25
Stifel Nicolaus Remains a Buy on Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
H.C. Wainwright
H.C. Wainwright
$120
Buy
113.07%
Upside
Reiterated
09/29/25
Cytokinetics' Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock OutlookValuation and potential impediments to achieving price target. We reiterate our Buy rating and $120 price target. Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate for capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.
B. Riley Securities Analyst forecast on CYTK
B. Riley Securities
B. Riley Securities
$74$80
Buy
42.05%
Upside
Reiterated
09/22/25
Cytokinetics price target raised to $80 from $74 at B. RileyCytokinetics price target raised to $80 from $74 at B. Riley
RBC Capital Analyst forecast on CYTK
RBC Capital
RBC Capital
$80$82
Buy
45.60%
Upside
Reiterated
09/08/25
RBC Capital Remains a Buy on Cytokinetics (CYTK)
Evercore ISI Analyst forecast on CYTK
Evercore ISI
Evercore ISI
$60$80
Buy
42.05%
Upside
Reiterated
09/03/25
Evercore ISI Sticks to Their Buy Rating for Cytokinetics (CYTK)
Citi
$77$84
Buy
49.15%
Upside
Reiterated
09/03/25
Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results
Jefferies Analyst forecast on CYTK
Jefferies
Jefferies
$80
Buy
42.05%
Upside
Reiterated
09/03/25
Cytokinetics (CYTK) Gets a Buy from Jefferies
Needham
$72
Buy
27.84%
Upside
Reiterated
09/02/25
Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials
Truist Financial Analyst forecast on CYTK
Truist Financial
Truist Financial
Buy
Reiterated
09/02/25
Cytokinetics (CYTK) Gets a Buy from Truist Financial
Leerink Partners Analyst forecast on CYTK
Leerink Partners
Leerink Partners
Buy
Reiterated
09/02/25
Buy Rating Justified for Cytokinetics Due to Aficamten's Advantages in HCM Treatment
UBS
$47$41
Hold
-27.20%
Downside
Reiterated
09/01/25
Cytokinetics (CYTK) Receives a Hold from UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month
xxx
Success Rate
13/18 ratings generated profit
72%
Average Return
+15.89%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +15.89% per trade.
3 Months
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+24.93%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +24.93% per trade.
1 Year
Salim SyedMizuho Securities
Success Rate
34/51 ratings generated profit
67%
Average Return
+30.15%
reiterated a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.15% per trade.
2 Years
xxx
Success Rate
35/51 ratings generated profit
69%
Average Return
+31.85%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.63% of your transactions generating a profit, with an average return of +31.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
38
28
17
24
22
Buy
11
7
1
9
9
Hold
10
13
15
17
11
Sell
3
2
0
0
0
Strong Sell
0
0
0
0
0
total
62
50
33
50
42
In the current month, CYTK has received 31 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 79.86.
Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.57 with a range of -$1.81 to -$1.29. The previous quarter’s EPS was -$1.12. CYTK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CYTK has Preformed in-line its overall industry.
Next quarter’s earnings estimate for CYTK is -$1.57 with a range of -$1.81 to -$1.29. The previous quarter’s EPS was -$1.12. CYTK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CYTK has Preformed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $6.05M with a range of $0.00 to $47.50M. The previous quarter’s sales results were $66.77M. CYTK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CYTK has Preformed in-line its overall industry.
Next quarter’s sales forecast for CYTK is $6.05M with a range of $0.00 to $47.50M. The previous quarter’s sales results were $66.77M. CYTK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CYTK has Preformed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 79.86.
    What is CYTK’s upside potential, based on the analysts’ average price target?
    Cytokinetics has 41.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CYTK a Buy, Sell or Hold?
          Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Cytokinetics’s price target?
            The average price target for Cytokinetics is 79.86. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 41.80% Increase from the current price of $56.32.
              What do analysts say about Cytokinetics?
              Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of CYTK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis